Arch Dermatol
The most recent articles from:
Arch Dermatol
-
Randomized Controlled Trial Multicenter Study
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
To determine the efficacy, safety, and sustainability of response to adalimumab therapy for moderate to severe chronic plaque psoriasis involving hands and/or feet. ⋯ Adalimumab is efficacious and well tolerated for treatment of chronic plaque psoriasis of hands and/or feet, with efficacy largely maintained to 28 weeks. Trial Registration clinicaltrials.gov Identifier: NCT00735787.
-
Randomized Controlled Trial
A pilot study of etanercept treatment for pemphigus vulgaris.